Additionally, it addresses the FDA’s communications Using the applicant, the retention of documents that guidance the SE report, confidentiality of an SE report, how an applicant can amend or withdraw an SE report, how an applicant might transfer possession of an SE report back to a completely new applicant and electronic submission in the SE rep